EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ZyVersa Therapeutics's Enterprise Value is $0.55 Mil.
ZyVersa Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.91 Mil. Therefore, ZyVersa Therapeutics's EV-to-FCF for today is -0.07.
The historical rank and industry rank for ZyVersa Therapeutics's EV-to-FCF or its related term are showing as below:
ZVSA'
s EV-to-FCF Range Over the Past 10 Years
Min: -1.05 Med: 0 Max: 0.1
Current: -0.07
During the past 4 years, the highest EV-to-FCF of ZyVersa Therapeutics was 0.10. The lowest was -1.05. And the median was 0.00.
ZVSA's EV-to-FCF is ranked worse than 100% of 382
companies
in the Biotechnology industry
Industry Median: 8.405
vs ZVSA: -0.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for ZyVersa Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ZyVersa Therapeutics's EV-to-FCF
For the Biotechnology subindustry, ZyVersa Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZyVersa Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ZyVersa Therapeutics's EV-to-FCF falls into.
ZyVersa Therapeutics's current Enterprise Value is $0.55 Mil.
ZyVersa Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ZyVersa Therapeutics's PE Ratio for today is calculated as:
ZyVersa Therapeutics's share price for today is $4.41.
ZyVersa Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1762.948.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ZyVersa Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of ZyVersa Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
ZyVersa Therapeutics (ZyVersa Therapeutics) Business Description
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are 1) Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. 2) IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZVSA has been successfully added to your 